

**Competing risk survival analysis in patients with symptomatic Waldenström macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy**

Efstathios Kastritis,<sup>1</sup> Marie-Christine Kyrtonis,<sup>2</sup> Pierre Morel,<sup>3</sup> Maria Gavriatopoulou,<sup>4</sup> Evdoxia Hatjiharissi,<sup>4</sup> Argirios S. Symeonidis,<sup>5</sup> Amalia Vassou,<sup>6</sup> Panagiotis Repousis,<sup>7</sup> Sossana Delimpasi,<sup>8</sup> Anastasia Sioni,<sup>9</sup> Evrydiki Michalis,<sup>10</sup> Michail Michael,<sup>11</sup> Elina Vervessou,<sup>12</sup> Michael Voulgarelis,<sup>13</sup> Costantinos Tsatalas,<sup>14</sup> Evangelos Terpos<sup>1</sup> and Meletios A. Dimopoulos<sup>1</sup>

<sup>1</sup>Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Greece; <sup>2</sup>Hematology Section of the First Department of Propedeutic Internal Medicine, Laikon University Hospital, National and Kapodistrian University of Athens, School of Medicine, Greece; <sup>3</sup>Service D'Hématologie Clinique et Thérapie Cellulaire CHU (University Hospital), Amiens, France; <sup>4</sup>Theagenion Cancer Center, Department of Hematology, Thessaloniki, Greece; <sup>5</sup>University of Patras, Hematology Division, Patras, Greece; <sup>6</sup>University of Ioannina, Hematology Division, Ioannina, Greece; <sup>7</sup>Peripheral General Anticancer Hospital-Metaxa, Department of Hematology, Piraeus, Greece; <sup>8</sup>Evangelismos Hospital, Hematology Department, Athens, Attica, Greece; <sup>9</sup>St Savvas Oncology Hospital, Hematology Division, Athens, Greece; <sup>10</sup>G. Gennimatas General Hospital, Department of Hematology, Athens, Greece; <sup>11</sup>Department of Haematology, Nicosia General Hospital, Cyprus; <sup>12</sup>Henry Dunant Hospital, Hematology Division, Athens, Greece; <sup>13</sup>Department of Pathophysiology, National And Kapodistrian University of Athens, School of Medicine, Greece; and <sup>14</sup>Democritus University of Thrace, Alexandroupolis, Greece

Correspondence: ekastritis@gmail.com  
doi:10.3324/haematol.2015.124149

Supplemental table : characteristics of the patients who have died by causes related or unrelated to WM

N=211	WM related (N=162)	WM unrelated (N=49)	P-value
Age (Median)	69	74	
>75 years	21%	43%	0.003
<50 years	6.6%	2%	
Indication for therapy			
Cytopenias	33%	51%	0.608
Hyperviscosity	24%	14%	
B-symptoms	8%	10%	
Organomegaly	14%	10%	
Cryoglobulinemia	3%	0%	
Neuropathy	3%	2%	
Other	16%	12%	
IPSS			
low	20%	11%	0.094
Intermediate	40%	39.5%	
High	40%	53.5%	
Hemoglobin<11.5 gr/dl	79.5%	73.5%	0.826
Platelets < 100 x 10 <sup>9</sup> /L	11.3%	20.4%	0.230
β-2 m >3 mg/dl	56%	61%	0.472
sAlbumin<3.5 gr/dl	43.6%	52%	0.519
LDH> 250 IU/L	27%	17%	0.199
Primary Tx Rituximab	33%	59%	0.003
Primary Tx Alkylators	65%	39%	
Primary Tx NAs*	2%	2%	
IgM reduction > 50%	48%	63%	0.06